Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Waldenström Macroglobulinemia (WM) Market Spotlight 2017: 10-Year Disease Incidence Forecast, Licensing and Acquisition Deals & Drug-Specific Revenue Forecasts - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Market Spotlight: Waldenström Macroglobulinemia (WM)" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Waldenström Macroglobulinemia market, comprising key pipeline and marketed drugs, clinical trials, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The author estimates that in 2016, there were approximately 4,600 incident cases of Waldenström macroglobulinemia in people aged 40 years and over worldwide, and forecasts that number to increase to 6,000 incident cases by 2025.
  • It is estimated that the majority of diagnosed cases worldwide were males in 2016. Worldwide, the incidence of Waldenström macroglobulinemia is highest amongst older individuals aged 60-79 years.
  • Imbruvica, a small molecule tyrosine kinase inhibitor, is the only approved drug by the US Food and Drug Administration for Waldenström macroglobulinemia.
  • The majority of industry-sponsored drugs in active clinical development for Waldenström macroglobulinemia are in Phase II, with only one drug in Phase III.
  • Therapies in mid-to-late-stage development for Waldenström macroglobulinemia focus on targets such as proteasome, Bruton's tyrosine kinase and cluster of differentiation 20. These drugs are administered via the oral, intravenous and subcutaneous routes.
  • There were only two licensing and asset acquisition activities involving Waldenström macroglobulinemia drugs during 2012-17. The clinical trials distribution across Phase I-IV indicates that the majority of trials for Waldenström macroglobulinemia have been in early and mid-phases of development, with 95.9% of trials in Phase I-II, and only 4.1% in Phase III.
  • The US has a substantial lead in the number of Waldenström macroglobulinemia clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
  • Clinical trial activity in the Waldenström macroglobulinemia space is dominated by completed trials.

Key Topics Covered:

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Chemotherapy

Targeted drugs

Biological therapy or Immunotherapy

Plasmapheresis

Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

BIBLIOGRAPHY

Prescription Information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/research/zwrlch/waldenstrm?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005749/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.